NEW YORK, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes CordenPharma's acquisition of Ancora Pharmaceuticals ' carbohydrate synthesis technology platform and the use of the corporate name of Ancora Pharmaceuticals. Ancora's technology and chemistry research facilities complement CordenPharma's capabilities in the manufacture and supply of high-quality complex synthetic molecules.
Harris & Harris Group Notes CordenPharma's Acquisition Of Ancora's Carbohydrate Synthesis Platform And Corporate Name
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.